A better understanding of this regulatory control may lead to a tumour‐specific vulnerability amenable to therapeutic interference in TNBC as well as other cancers known to express high levels of ID1, including pancreatic (shown here), bladder [71], brain [72], head and neck [73], ovarian [74] and more (reviewed in Ref. This evidence concerns the gene ID1 and neoplasm.